Increase in Prevalence of Chronic Diseases, Globally, Driving the Red Biotechnology Market
Increasing number of chronic and rare disease across the globe is anticipated to fuel the global red biotechnology market during the forecast period, due to the increasing patient population, which, in turn, is expected to drive the demand for novel drug molecules for the effective treatment of diseases.
According to WHO, there are approximately 6,000 to 8,000 rare diseases, and out of them, nearly 80% are genetic disorders. Therefore, the increasing demand for therapeutics and diagnostics for rapid and efficient diseases management, coupled with increasing incidences and prevalence of chronic and rare diseases, is expected to propel the red biotechnology market, globally, during the forecast period.
Request a PDF Sample of Red Biotechnology Market Report –
Gene Therapy to be a Promising Segment of the Global Red Biotechnology Market
Based on application, the global red biotechnology market has been divided into biopharmaceutical production, gene therapy, pharmacogenomics, and genetic testing. The gene therapy segment of the red biotechnology market is projected to expand at a high CAGR during the forecast period, owing to increasing research for the development of therapeutics to treat various genetic disorders responsible for rare diseases.
For instance, in 2019, CELGENE CORPORATION, together with Bluebird Bio, Inc., declared results from a Phase 1 clinical study for bb2121 anti-BCMA CAR T Cell Therapy in individuals suffering from multiple myeloma.
Request for a Discount on Red Biotechnology Market Report –
Biopharmaceutical Product Segment Prominent in the Red Biotechnology Market
In terms of end user, the global red biotechnology market has been segmented into biopharmaceutical industries, CMOs & CROs, research institutes, and others. The biopharmaceutical industries segment is expected to hold a prominent share of the global red biotechnology market during the forecast period.
Major drivers that are attributed to boost this segment of the red biotechnology market during the forecast period are increasing investments in research & development by major players and establishing newer facilitates to cope up with the growing demand, increasing product approvals, and strong pipeline of drug products in clinical trials. For instance, in February 2018, Merck invested in the establishment of a cell culture facility in South Korea. It also entered into agreements to establish a manufacturing and distribution center in India.
On May 2019, Pfizer announced the Phase 3 result for LYRICA (pregabalin) in primary generalized tonic-clonic seizures. Thus, increasing investments in research and development, along with a rise in the number of drug candidates in early and late phases of clinical trials is expected to drive the biopharmaceutical industries segment of the global red biotechnology market during the forecast period.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.
Mr. Rohit Bhisey
Transparency Market Research
90 State Street,
Albany NY – 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]